Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.765 +0.355 (+4.79%)
Streaming Delayed Price Updated: 3:44 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Colorado Patients Reap Benefits of Ketamine Treatments for Depression
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Preclinical Data from CYB004 Study Showing Significant Advantages
Via Investor Brand Network
Oregon to Become the First State to Legally Roll Out Psilocybin
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in... 
Via FinancialNewsMedia
Topics Derivatives ETFs
Exposures Derivatives
Depression Causes Lasting Physiological Alterations to Immunity Cells
Via Investor Brand Network
Three Kinds of Trauma Psychedelics Hope to Treat
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference
Via Investor Brand Network
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
From Cybin Inc.
Via Business Wire
Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
Via Investor Brand Network
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release
Via Investor Brand Network
Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study
Via Investor Brand Network
Why Psychedelics Could Soon Replace Antidepressants
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults... 
Via FinancialNewsMedia
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
From Cybin Inc.
Via Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position of Psychedelic Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Further Strengthens Long-Term IP Position of Psychedelic-Based Programs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space
Via Investor Brand Network
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
From Cybin Inc.
Via Business Wire
Cybi (NEO: CYBN) (NYSE American: CYBN) to Participate in Benzinga Psychedelics Conference
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference
Via Investor Brand Network
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
From Cybin Inc.
Via Business Wire
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Achieves New Milestone
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone
Via Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Study
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development
Via Investor Brand Network
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.